Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
European shares jump on Ukraine ceasefire hopes; Zealand Pharma soars
European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, while ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...
Contract Pharma2d
Roche, Zealand Pharma Partner to Co-Develop & Co-Commercialize Obesity Therapy
Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...
Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...
PharmExec2d
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.